Cited by 355Cannabis and Cannabinoid ResearchParkinson's Disease Mechanisms and TreatmentsSchizophrenia research and treatment

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

Cannabidiol for the treatment of psychosis in Parkinson's disease

Zuardi, AW, Crippa, Jas, Hallak, JEC, Pinto, JP, Chagas, MHN, Rodrigues, GGR, Dursun, SM, Tumas, V.·2009·Journal of Psychopharmacology

DOI 10.1177/0269881108096519

Open this paper in CoChat — free account

Abstract

The management of psychosis in Parkinson's disease (PD) has been considered a great challenge for clinicians and there is a need for new pharmacological intervention. Previously an antipsychotic and neuroprotective effect of Cannabidiol (CBD) has been suggested. Therefore, the aim of the present study was to directly evaluate for the first time, the efficacy, tolerability and safety of CBD on PD patients with psychotic symptoms. This was an open-label pilot study. Six consecutive outpatients (four men and two women) with the diagnosis of PD and who had psychosis for at least 3 months were selected for the study. All patients received CBD in flexible dose (started with an oral dose of 150 mg/day) for 4 weeks, in addition to their usual therapy. The psychotic symptoms evaluated by the Brief Psychiatric Rating Scale and the Parkinson Psychosis Questionnaire showed a significant decrease under CBD treatment. CBD did not worsen the motor function and decreased the total scores of the Unified Parkinson's Disease Rating Scale. No adverse effect was observed during the treatment. These preliminary data suggest that CBD may be effective, safe and well tolerated for the treatment of the psychosis in PD.

Integrity signals

Registry

Crossref · 10.1177/0269881108096519

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The FAB: A frontal assessment battery at bedside
Dubois, B., Slachevsky, A., Litvan, I., & Pillon, B. (2000) · Neurology · doi:10.1212/wnl.55.11.1621 · Cited by 3,913
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568
Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
Fénelon, G. (2000) · Brain · doi:10.1093/brain/123.4.733 · Cited by 1,035
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder, C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L., & Mitchell, R. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10492-6 · Cited by 900
Cannabidiol displays unexpectedly high potency as an antagonist of CB 1 and CB 2 receptor agonists in vitro
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 763
Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group
Ravina, B., Marder, K., Fernandez, H. H., Friedman, J. H., McDonald, W., Murphy, D., Aarsland, D., Babcock, D., Cummings, J., Endicott, J., et al. (2007) · Movement Disorders · doi:10.1002/mds.21382 · Cited by 528
Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes.
Bech, P., Kastrup, M., & Rafaelsen, O. J. (1986) · PubMed · Cited by 467
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 415
Self-citation

Show all 30 references

Research works printed but not linked: 7

Bech, P., 1986, Acta Psychiatr Scand Suppl, 326, 1
10.1111/j.1460-9568.1998.00292.x · DOI
Fahn, S., Elton, RL Members of the UPDRS Development Committee ( 1987) Unified Parkinson’s Disease Rating Scale (UPDRS) . In: Fahn, S, Marsden, CD, Calne, DB , Goldstein, M (eds), Recent Developments in Parkinson’s Disease, Vol. 2. Florahm Park, NJ: Macmillan Health Care Information , pp. 153-164.
First, MB, 1997, Structured Clinical Interview for DSM-IV Axis I Disorders - Clinician Version (SCID-CV)
National Institute of Mental Health (1976) CGI - Clinical Global Impression. In: Guy, W (ed), ECDEU Assessment Manual of Psychopharmacology (revised) . Rockville, MD: NIMH, pp. 534- 537.
Zuardi, AW, 1994, Rev ABPAPAL, 16, 63
Zuardi, AW, 1995, J Clin Psychiatry, 56, 485

Sorted by citations

Items 101–200 of 354

Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial
Leweke, F. M., Rohleder, C., Gerth, C. W., Hellmich, M., Pukrop, R., & Koethe, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.614811 · Cited by 53
Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, and Cognitive and Physical Performance
Jîtcă, G., Ősz, B. E., Vari, C.-E., Rusz, C.-M., Tero-Vescan, A., & Puşcaş, A. (2023) · Antioxidants · doi:10.3390/antiox12020485 · Cited by 58
The Impact of Cannabidiol on Psychiatric and Medical Conditions
Oberbarnscheidt, T., & Miller, N. S. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4159 · Cited by 55
Neuroprotective therapeutics from botanicals and phytochemicals against Huntington's disease and related neurodegenerative disorders
Dey, A., & De, J. N. (2015) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2015.01.002 · Cited by 52
Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition
Colizzi, M., Ruggeri, M., & Bhattacharyya, S. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.00833 · Cited by 51
Neuropsychiatry of Parkinson's disease
Kümmer, A., & Teixeira, A. L. (2009) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2009000500033 · Cited by 49
Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson’s Disease and l-DOPA-Induced Dyskinesia
Ferreira‐Junior, N. C., Pereira, M. D. S., Guimarães, F. S., & Bel, E. D. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00109-8 · Cited by 53
Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial
McCartney, D., Suraev, A. S., Doohan, P. T., Irwin, C. G., Kevin, R. C., Grunstein, R. R., Hoyos, C. M., & McGregor, I. S. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221095356 · Cited by 51
Treating Alzheimer’s disease using nanoparticle-mediated drug delivery strategies/systems
Roghani, A. K., Garcia, R. I., Roghani, A., Reddy, A. P., Khemka, S., Reddy, R. P., Pattoor, V., Jacob, M., Reddy, P. H., & Sehar, U. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102291 · Cited by 53
From Real-World Events to Psychosis: The Emerging Neuropharmacology of Delusions
Morrison, P. D., & Murray, R. M. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp049 · Cited by 48
Emerging potential of cannabidiol in reversing proteinopathies
Dash, R., Ali, M. C., Jahan, I., Munni, Y. A., Mitra, S., Hannan, M. A., Timalsina, B., Oktaviani, D. F., Choi, H. J., & Moon, I. S. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101209 · Cited by 50
Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028—study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation
Costiniuk, C. T., Saneei, Z., Routy, J., Margolese, S. L., Mandarino, E., Singer, J., Lebouché, B., Cox, J., Szabo, J., Brouillette, M., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024793 · Cited by 46
Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration
Yau, G. T. Y., Tai, W., Arnold, J. C., Chan, H., & Kwok, P. C. L. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03469-1 · Cited by 48
Does cannabidiol have a role in the treatment of schizophrenia?
Gururajan, A., & Malone, D. T. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.06.022 · Cited by 51
Changes in the composition of cannabis from 2000–2017 in Denmark: Analysis of confiscated samples of cannabis resin.
Thomsen, K. R., Lindholst, C., Thylstrup, B., Kvamme, S. L., Reitzel, L. A., Worm‐Leonhard, M., Englund, A., Freeman, T. P., & Hesse, M. (2019) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000303 · Cited by 44
Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats
Kozela, E., Krawczyk, M., Kos, T., Juknat, A., Vogel, Z., & Popik, P. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01831-2 · Cited by 45
Cannabidiol and substance use disorder: Dream or reality
Karimi‐Haghighi, S., Razavi, Y., Iezzi, D., Scheyer, A. F., Manzoni, O. J., & Haghparast, A. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108948 · Cited by 46
Protective Effects of Cannabidiol on Lesion-Induced Intervertebral Disc Degeneration
Silveira, J. W. S., Issy, A. C., Castania, V., Salmón, C. E. G., Nogueira‐Barbosa, M. H., Guimarães, F. S., Defino, H. L. A., & Bel, E. A. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113161 · Cited by 42
Evidence for the use of cannabinoids in Parkinson’s disease
Buhmann, C., Mainka, T., Ebersbach, G., & Gandor, F. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02018-8 · Cited by 42
Neurobiological findings underlying depressive behavior in Parkinson’s disease: A review
Mendonça, I. P., Duarte-Silva, E. P., Chaves-Filho, A. J. M., Andrade‐da‐Costa, B. L. D. S., & Peixoto, C. A. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106434 · Cited by 42
Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies
Reddy, V. P., Grogan, D. P., Ahluwalia, M., Salles, É. L., Ahluwalia, P. K., Khodadadi, H., Alverson, K., Nguyen, A., Raju, S. P., Gaur, P., et al. (2020) · The EPMA Journal · doi:10.1007/s13167-020-00203-4 · Cited by 45
The Effects of Cannabidiol Oil on Noninvasive Measures of Muscle Damage in Men
Cochrane-Snyman, K. C., Cruz, C. O. D. L., Morales, J. O., & COLES, M. (2021) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002606 · Cited by 46
Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders
Scarante, F. F., Ribeiro, M. A., Almeida-Santos, A. F., Guimarães, F. S., & Campos, A. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.618065 · Cited by 44
Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
Chesney, E., Oliver, D., & McGuire, P. (2022) · Psychopharmacology · doi:10.1007/s00213-021-05905-9 · Cited by 40
Cannabis and psychosis: Have we found the missing links?
Parakh, P., & Basu, D. (2013) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2013.03.012 · Cited by 41
Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations
Aziz, A.-I., Nguyen, L. C., Oumeslakht, L., Bensussan, A., & Mkaddem, S. B. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0133 · Cited by 41
Cannabis use as a risk factor for psychotic‐like experiences: A systematic review of non‐clinical populations evaluated with the Community Assessment of Psychic Experiences
Ragazzi, T. C. C., Shuhama, R., Menezes, P. R., & Del‐Ben, C. M. (2018) · Early Intervention in Psychiatry · doi:10.1111/eip.12693 · Cited by 40
Biological bases for a possible effect of cannabidiol in Parkinson’s disease
Ferreira‐Junior, N. C., Campos, A. C., Guimarães, F. S., Bel, E. A. D., Zimmermann, P. M. D. R., Brum, L., Hallak, J. E. C., Crippa, J. A. S., & Zuardi, A. W. (2019) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0460 · Cited by 44
Self-citation
Virtual screening using docking and molecular dynamics of cannabinoid analogs against CB1 and CB2 receptors
Alviz-Amador, A., Contreras‐Puentes, N., & Mercado‐Camargo, J. (2021) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2021.107590 · Cited by 39
Nepalese traditional medicine and symptoms related to Parkinson׳s disease and other disorders: Patterns of the usage of plant resources along the Himalayan altitudinal range
Jacquet, A. D. R., Subedi, R., Ghimire, S. K., & Rochet, J. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.02.016 · Cited by 37
Medical cannabis as an alternative therapeutics for Parkinsons’ disease: Systematic review
Bougea, A. M., Koros, C., Simitsi, A., Chrysovitsanou, C., Leonardos, A., & Stefanis, L. (2020) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2020.101154 · Cited by 36
Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance
Martini, S., Gemma, A., Ferrari, M., Cosentino, M., & Marino, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043125 · Cited by 39
The Protective Mechanism of Cannabidiol in Cardiac Injury: A Systematic Review of Non-Clinical Studies
Shayesteh, M. R. H., Haghi‐Aminjan, H., Mousavi, M. J., Momtaz, S., & Abdollahi, M. R. (2019) · Current Pharmaceutical Design · doi:10.2174/2210327909666190710103103 · Cited by 35
Therapeutic Applications of Cannabinoids in Cardiomyopathy and Heart Failure
Garza-Cervantes, J. A., Ramos-González, M. R., Lozano, O., Carlos Jerjes-Sánchez, D., & García‐Rivas, G. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/4587024 · Cited by 38
Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice
Paes-Colli, Y., Aguiar, A. F. L., Isaac, A. R., Ferreira, B. K., Campos, R. M. P., Trindade, P. M. P., Reis, R. A. D. M., & Sampaio, L. D. S. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.917164 · Cited by 39
Beyond Pain Relief: A Review on Cannabidiol Potential in Medical Therapies
Veiga, M., Azevedo‐Silva, J., & Fernandes, J. C. (2023) · Pharmaceuticals · doi:10.3390/ph16020155 · Cited by 36
Cannabis for the treatment of amyotrophic lateral sclerosis: What is the patients’ view?
Lacroix, C., Guilhaumou, R., Micallef, J., Bruneteau, G., Desnuelle, C., & Blin, O. J. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2023.03.018 · Cited by 33
Cannabinoids and Dementia: A Review of Clinical and Preclinical Data
Walther, S., & Halpern, M. (2010) · Pharmaceuticals · doi:10.3390/ph3082689 · Cited by 32
The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease
Han, Q.-W., Yuan, Y., & Chen, N. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109745 · Cited by 37
Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions
Behl, T., Kaur, G., BUNGAU, S. G., Jhanji, R., Kumar, A., Mehta, V., Zengin, G., Brata, R. D., Hassan, S. S. U., & Frățilă, O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176235 · Cited by 34
Could cannabidiol be used as an alternative to antipsychotics?
Fakhoury, M. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.05.013 · Cited by 33
G-protein coupled receptors as therapeutic targets for neurodegenerative and cerebrovascular diseases
Guerram, M., Zhang, L., & Jiang, Z. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.09.005 · Cited by 32
Marijuana Compounds: A Nonconventional Approach to Parkinson’s Disease Therapy
Babayeva, M., Assefa, H., Basu, P., Chumki, S. R., & Loewy, Z. G. (2016) · Parkinson s Disease · doi:10.1155/2016/1279042 · Cited by 38
Nabilone for non-motor symptoms of Parkinson’s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study)
Peball, M., Werkmann, M., Ellmerer, P., Stolz, R., Valent, D., Knaus, H., Ulmer, H., Djamshidian, A., Poewe, W. H., & Seppi, K. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02021-z · Cited by 31
Conversion Characteristics of Some Major Cannabinoids from Hemp (Cannabis sativa L.) Raw Materials by New Rapid Simultaneous Analysis Method
Ryu, B. R., Islam, J., Azad, M. O. K., Go, E.-J., Rahman, M. H., Rana, M. S., Lim, Y.-S., & Lim, J. D. (2021) · Molecules · doi:10.3390/molecules26144113 · Cited by 31
Cannabinoids as anticancer and neuroprotective drugs: Structural insights and pharmacological interactions—A review
Pugazhendhi, A., Suganthy, N., Chau, T. P., Sharma, A. K., Unpaprom, Y., Ramaraj, R., Karuppusamy, I., & Brindhadevi, K. (2021) · Process Biochemistry · doi:10.1016/j.procbio.2021.08.025 · Cited by 32
THC and CBD Fingerprinting of an Elite Cannabis Collection from Iran: Quantifying Diversity to Underpin Future Cannabis Breeding
Dehnavi, M. M., Ebadi, A., Peirovi, A., Taylor, G., & Salami, S. A. (2022) · Plants · doi:10.3390/plants11010129 · Cited by 31
Cannabinoids in Late Life Parkinson’s Disease and Dementia: Biological Pathways and Clinical Challenges
Costa, A. C., Joaquim, H. P. G., Pedrazzi, J. F. C., Pain, A. D. O., Duque, G., & Aprahamian, I. (2022) · Brain Sciences · doi:10.3390/brainsci12121596 · Cited by 38
Crosstalk between the endocannabinoid and mid-brain dopaminergic systems: Implication in dopamine dysregulation
Kibret, B. G., Canseco-Alba, A., Onaivi, E. S., & Engidawork, E. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1137957 · Cited by 30
Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?
Lee, D., Karschner, E. L., Milman, G., Barnes, A. J., Goodwin, R. S., & Huestis, M. A. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.10.011 · Cited by 29
The future of type 1 cannabinoid receptor allosteric ligands
Alaverdashvili, M., & Laprairie, R. B. (2018) · Drug Metabolism Reviews · doi:10.1080/03602532.2018.1428341 · Cited by 29
Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy
Peres, F. F., Levin, R. R., de Almeida, V., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A. S., & Abílio, V. C. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00303 · Cited by 28
Self-citation
Cannabinoids in the management of behavioral, psychological, and motor symptoms of neurocognitive disorders: a mixed studies systematic review
Bahji, A., Breward, N. J., DUFF, W. R. D., Absher, N., Patten, S. B., Alcorn, J., & Mousseau, D. D. (2022) · Journal of Cannabis Research · doi:10.1186/s42238-022-00119-y · Cited by 29
Medicinal Cannabis and Central Nervous System Disorders
Ortiz, Y. T., McMahon, L. R., & Wilkerson, J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.881810 · Cited by 29
Marijuana on the Mind? The Impact of Marijuana on Cognition, Brain Structure, and Brain Function, and Related Public Policy Implications
Gruber, S. A., & Sagar, K. A. (2017) · Policy Insights from the Behavioral and Brain Sciences · doi:10.1177/2372732216684851 · Cited by 28
Cannabis in Parkinson’s Disease — the patient’s perspective versus clinical trials: a systematic literature review
Figura, M., Koziorowski, D., & Sławek, J. (2022) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2022.0004 · Cited by 26
Cannabinoids in Treating Parkinson's Disease Symptoms: A Systematic Review of Clinical Studies
Varshney, K., Patel, A. J., Ansari, S., Shet, P., & Panag, S. S. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2023.0023 · Cited by 26
The Therapeutic Potential of the Endocannabinoid System in Age-Related Diseases
Tudorancea, I. M., Ciorpac, M., Stanciu, G. D., Caratașu, C.-C., Săcărescu, A., Ignat, B. E., Burlui, A., Rezuş, E., Creangă-Murariu, I., Alexa‐Stratulat, T., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10102492 · Cited by 28
Recommendation to reconsider examining cannabis subtypes together due to opposing effects on brain, cognition and behavior.
Rømer Thomsen, K., Callesen, M. B., & Feldstein Ewing, S. W. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.025 · Cited by 24
Cannabis-Based Phytocannabinoids: Overview, Mechanism of Action, Therapeutic Application, Production, and Affecting Environmental Factors
Jurga, M., Jurga, A., Jurga, K., Kaźmierczak, B., Kuśmierczyk, K., & Chabowski, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011258 · Cited by 30
The Use of Cannabinoids in Treating Dementia
Weier, M., & Hall, W. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0766-6 · Cited by 25
Medicinal cannabis: knowledge, beliefs, and attitudes of Colombian psychiatrists
Orjuela-Rojas, J. M., Orjuela, X. G., & Ocampo-Serna, S. (2021) · Journal of Cannabis Research · doi:10.1186/s42238-021-00083-z · Cited by 24
Higher Risk, Higher Reward? Self‐Reported Effects of Real‐World Cannabis Use in Parkinson's Disease
Holden, S. K., Domen, C. H., Sillau, S., Liu, Y., & Leehey, M. A. (2022) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13414 · Cited by 24
How long does a single oral dose of cannabidiol persist in plasma? Findings from three clinical trials
McCartney, D., Kevin, R. C., Suraev, A. S., Sahinovic, A., Doohan, P. T., Bedoya‐Pérez, M. A., Grunstein, R. R., Hoyos, C. M., & McGregor, I. S. (2022) · Drug Testing and Analysis · doi:10.1002/dta.3419 · Cited by 25
Cannabis and Neuropsychiatric Disorders: An Updated Review.
Chayasirisobhon, S. (2019) · PubMed · Cited by 26
Cannabidiol in Parkinson’s disease
Rieder, C. R. D. M. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0810 · Cited by 23
Component of Cannabis, Cannabidiol, as a Possible Drug against the Cytotoxicity of Aβ(31–35) and Aβ(25–35) Peptides: An Investigation by Molecular Dynamics and Well-Tempered Metadynamics Simulations
Chrobak, W., Pacut, D. W., Blomgren, F., Rodin, A., Swenson, J., & Ermilova, I. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00692 · Cited by 23
Cannabidiol in Foods and Food Supplements: Evaluation of Health Risks and Health Claims
Engeli, B. E., Lachenmeier, D. W., Diel, P. R., Guth, S., Villar-Fernandez, M., Roth, A., Lampen, A., Cartus, A. T., Wätjen, W., Hengstler, J. G., et al. (2025) · Nutrients · doi:10.3390/nu17030489 · Cited by 23
Investigation of the effects of cannabidiol on vacuous chewing movements, locomotion, oxidative stress and blood glucose in rats treated with oral haloperidol
Kajero, J. A., Seedat, S., OHAERI, J. U., Akindele, A. J., & Aina, O. O. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1752934 · Cited by 22
The Role of Cannabidiol in Neurological Disorders
Chayasirisobhon, S. (2021) · The Permanente Journal · doi:10.7812/tpp/20.156 · Cited by 28
Therapeutic considerations of bioactive compounds in Alzheimer's disease and Parkinson's disease: Dissecting the molecular pathways
Phukan, B. C., Roy, R., Gahatraj, I., Bhattacharya, P., & Borah, A. (2023) · Phytotherapy Research · doi:10.1002/ptr.8012 · Cited by 22
Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders
Sampaio, M. D. F. D. S., de Paiva, Y. B., Sampaio, T. B., Pereira, M. G., & Coimbra, N. C. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13997 · Cited by 28
The effect of cannabidiol on simulated car driving performance: A randomised, double‐blind, placebo‐controlled, crossover, dose‐ranging clinical trial protocol
McCartney, D., Benson, M. J., Suraev, A. S., Irwin, C. G., Arkell, T. R., Grunstein, R. R., Hoyos, C. M., & McGregor, I. S. (2020) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2749 · Cited by 21
Treating hallucinations in Parkinson’s disease
Powell, A., Matar, E., & Lewis, S. J. G. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1851198 · Cited by 21
Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies
Pisani, S., McGoohan, K., Velayudhan, L., & Bhattacharyya, S. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00882-2 · Cited by 22
The role of cannabidiol in aging
Ni, B., Liu, Y., Dai, M., Zhao, J., Yu, L., Yang, X. C., Han, B., & Jiang, M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115074 · Cited by 21
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review
Dammann, I., Rohleder, C., & Leweke, F. M. (2024) · Pharmacopsychiatry · doi:10.1055/a-2228-6118 · Cited by 24
Cannabinoids in Health and Disease
Meccariello, R., & Chianese, R. (2016) · InTech eBooks · doi:10.5772/61595 · Cited by 22
Cannabinoids for behavioral symptoms in severe dementia: Safety and feasibility in a long-term pilot observational study in nineteen patients
Pautex, S., Bianchi, F., Daali, Y., Augsburger, M. P., de Saussure, C., Wampfler, J., Curtin, F., Desmeules, J. A., & Broers, B. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.957665 · Cited by 20
Molecular Imaging of the Cannabinoid System in Idiopathic Parkinson's Disease
Cilia, R. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.08.004 · Cited by 20
The role of cannabinoids and leptin in neurological diseases
Agar, E. (2015) · Acta Neurologica Scandinavica · doi:10.1111/ane.12411 · Cited by 21
Interaction of Cannabis Use and Aging: From Molecule to Mind
Yoo, H. B., DiMuzio, J. M., & Filbey, F. M. (2019) · Journal of Dual Diagnosis · doi:10.1080/15504263.2019.1665218 · Cited by 21
The United Chemicals of Cannabis: Beneficial Effects of Cannabis Phytochemicals on the Brain and Cognition
Weston–Green, K. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79266 · Cited by 19
A single oral dose of cannabidiol did not reduce upper limb tremor in patients with essential tremor
de Alencar, S. S., Crippa, J. A. S., Brito, M. M. C. M., Pimentel, Â. V., Hallak, J. E. C., & Tumas, V. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.01.001 · Cited by 18
Self-citation
Biological activity of Cannabis compounds: a modern approach to the therapy of multiple diseases
Helcman, M., & Šmejkal, K. (2021) · Phytochemistry Reviews · doi:10.1007/s11101-021-09777-x · Cited by 18
Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson’s Disease
Ferreira, C., de Almeida, M. C. M. D., Tenreiro, S., & Quintas, A. (2020) · Life · doi:10.3390/life10060086 · Cited by 19
Temperature Controlled Loading and Release of the Anti-Inflammatory Drug Cannabidiol by Smart Microgels
Dirksen, M., Kinder, T. A., Brändel, T., & Hellweg, T. (2021) · Molecules · doi:10.3390/molecules26113181 · Cited by 18
Therapeutic use of medical Cannabis in neurological diseases: a clinical update
Hidding, U., Mainka, T., & Buhmann, C. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02719-1 · Cited by 42
What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?
Lacroix, C., Alleman-Brimault, I., Zalta, A., Rouby, F., Cassé‐Perrot, C., Jouve, É., Attolini, L., Guilhaumou, R., Micallef, J., & Blin, O. J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.883987 · Cited by 16
The Effect of Antipsychotics on Cognition in Schizophrenia—A Current Narrative Review
Lungu, P. F., Lungu, C. M., Ciobica, A. S., Balmuș, I.-M., Vitalaru, R., Mavroudis, I. A., Dobrin, R., Cîmpeanu, M., & Gurzu, I. L. (2024) · Brain Sciences · doi:10.3390/brainsci14040359 · Cited by 16
Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis
Crippa, J. A., Hallak, J. E. C., Abílio, V. C., de Lacerda, A., & Zuardi, A. W. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527314666150909113930 · Cited by 17
Self-citation
Modulation of cognitive and emotional processing by cannabidiol: the role of the anterior cingulate cortex
Kowal, M. A., Hazekamp, A., Colzato, L. S., van Steenbergen, H., & Hommel, B. (2013) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2013.00147 · Cited by 16
The impact of medical marijuana laws on marijuana use and other risky health behaviors
Choi, A. (2014) · Health & Healthcare in America: From Economics to Policy · Cited by 15
A reliable quantitative method for determining CBD content and release from transdermal patches in Franz cells
Yu, L., Madsen, F. B., Eriksen, S. H., Andersen, A. J. C., & Skov, A. L. (2022) · Phytochemical Analysis · doi:10.1002/pca.3188 · Cited by 15
Cannabinoids in the treatment of movement disorders: A systematic review of case series and clinical trials
Andrzejewski, K. L., Barbano, R. L., & Mink, J. W. (2016) · Basal Ganglia · doi:10.1016/j.baga.2016.06.001 · Cited by 14
PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice
Sonego, A. B., Prado, D. D. S., & Guimarães, F. S. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110367 · Cited by 15
Sila-CBD Derivatives as Inhibitors of Heme-Induced NLRP3 Inflammasome: Application in Hemolytic Diseases
Shete, S. S., Iqbal, F., Bhardwaj, M., Nandi, U., Kumar, A., & Reddy, D. S. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00352 · Cited by 13
Cannabinoids in movement disorders
Kluger, B. M., Huang, A. P., & Miyasaki, J. M. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.08.014 · Cited by 16
Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics
Butala, A., Shepard, M. D., & Pontone, G. M. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00007-1 · Cited by 13
Cannabidiol reduces lesion volume and restores vestibulomotor and cognitive function following moderately severe traumatic brain injury
Friedman, L. K., Peng, H., & Zeman, R. J. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113844 · Cited by 13

Authors: Zuardi, A., Crippa, J., Hallak, J., Pinto, J., Chagas, M., Rodrigues, G., Dursun, S., & Tumas, V.
Affiliations: Universidade de São Paulo (BR)
Department of Neuropsychiatry and Medical Psychology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
Corresponding author: Zuardi, AW
ORCID: Tumas, V.
Venue: Journal of Psychopharmacology
Publisher: SAGE Publications
Published: 2008-09-18
Volume: 23
Issue: 8
Pages: 979-983
ISSN: 0269-8811 (ISSN-L)
1461-7285
DOI: 10.1177/0269881108096519
OpenAlex: W1967281437
Cited by: 355
References: 30
Citations by year: 2026: 14 · 2025: 15 · 2024: 28 · 2023: 34 · 2022: 28 · 2021: 33 · 2020: 39 · 2019: 29 · 2018: 21 · 2017: 20 · 2016: 17 · 2015: 12 · 2014: 14 · 2013: 8 · 2012: 9
FWCI: 7.24
Type: journal article
Language: en
Open access: closed
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Journal of Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
Funders: Fundação de Amparo à Pesquisa do Estado de São Paulo
Conselho Nacional de Desenvolvimento Científico e Tecnológico
National Institutes of Health
National Institute of Mental Health
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords: cannabidiol, Parkinson's disease, psychosis, antipsychotic drugs, neuroprotection, motor function, drug safety and tolerability, Brief Psychiatric Rating Scale
MeSH terms: Adult, Aged, Cannabidiol, Female, Humans, Male, Middle Aged, Parkinson Disease, Pilot Projects, Psychotic Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cannabidiol for the treatment of psychosis in Parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks